In 2010, we put forward a hypothetical model of the major biomarkers of Alzheimer's disease
(AD). The model was received with interest because we described the temporal evolution of …

Currently available evidence strongly supports the position that the initiating event in
Alzheimer's disease (AD) is related to abnormal processing of β-amyloid (Aβ) peptide, ultimately …

Background: PET imaging using [ 18 F]fluorodeoxyglucose (FDG) and [ 11 C]Pittsburgh
compound B (PIB) have been proposed as biomarkers of Alzheimer disease (AD), as have CSF …

The National Institute on Aging and the Alzheimer’s Association charged a workgroup with
the task of developing criteria for the symptomatic predementia phase of Alzheimer’s disease (…

Importance Cerebral amyloid-β aggregation is an early pathological event in Alzheimer
disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid …

Background: Neuroimaging measures and chemical biomarkers may be important indices
of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be …

Biomarkers have become an essential component of Alzheimer disease (AD) research and
because of the pervasiveness of AD pathology in the elderly, the same biomarkers are used …

ContextDeficits in cerebral glucose utilization have been identified in patients with cognitive
dysfunction attributed to various disease processes, but their prognostic and diagnostic …

Tau pathology is a hallmark of Alzheimer's disease (AD) but also occurs in normal cognitive
aging. Using the tau PET agent 18 F-AV-1451, we examined retention patterns in cognitively …

See Sarazin et al . (doi: 10.1093/brain/aww041 ) for a scientific commentary on this article.
The advent of the positron emission tomography tracer 18 F-AV1451 provides the unique …